ReviewJournal of lipid research2016
Lipoprotein apheresis to treat elevated lipoprotein (a).
Review in Journal of lipid research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- The Impact of Lipoprotein apheresis on Plasma Protein Levels: A Meta-Analysis.Journal of clinical apheresis · 2026Pooled it
- Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial.European heart journal · 2026Trial
- GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases.Current atherosclerosis reports · 2026Review
- Expert consensus on Lipoprotein(a) in the Gulf countries: Navigating cardiovascular risk and therapeutic advances.Atherosclerosis plus · 2026Article
- Novel Lipoprotein (a) Therapies: A Comprehensive Review.Current atherosclerosis reports · 2026Review
- Lipoprotein(a) in Coronary Artery Disease and Aortic Stenosis: Pathophysiology, Clinical Impact, Interventional Implications and Emerging Targeted Therapies.Journal of clinical medicine · 2026Review
- Emerging Therapies Targeting Lipoprotein(a): A Clinical Trial Landscape Review of Investigational Lp(a)-Lowering Therapies.Journal of clinical medicine · 2026Review
- Managing Progressive Atherosclerotic Cardiovascular Disease in a Patient with Elevated Lipoprotein(a).Anatolian journal of cardiology · 2026Review
- Kidney transplantation beyond immunosuppression: shifting the focus from graft survival to patient health.Frontiers in immunology · 2026Review
- Lipoprotein(a) in clinical practice: Risk stratification and therapeutic strategies.European journal of clinical investigation · 2026Review
- Navigating hypertriglyceridemia in pregnancy: current evidence and clinical strategies.Frontiers in endocrinology · 2026Review
- Lipoprotein(a) in cardiovascular disease: pathophysiology, residual risk, and emerging therapeutic strategies.Frontiers in medicine · 2026Review
- Zerlasiran for Lipoprotein(a) Reduction: Mechanisms, Evidence, and Future Directions.Cardiovascular & hematological disorders drug targets · 2026Review
- Lowering of Lipoprotein(a) with Olpasiran.Cardiovascular & hematological disorders drug targets · 2026Review
- Peripheral arterial disease associated with elevated lipoprotein(a): a review of the evidence and treatment approaches.Current opinion in lipidology · 2025Review
- Patient Experience of Heart Disease with Elevated Lipoprotein(a): Views from a Patient, His Physician, and a Patient Association.Cardiology and therapy · 2025Article
- Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease in South Asian Individuals.Journal of the American Heart Association · 2025Review
- Therapeutic Plasma Exchange: Current and Emerging Applications to Mitigate Cellular Signaling in Disease.Biomolecules · 2025Review
- 2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.Archives of medical science : AMS · 2025Article
- Lipoprotein (a): Underrecognized Risk with a Promising Future.Reviews in cardiovascular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An elevated plasma concentration of lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease. Life style modification and currently available drugs either fail to effectively lower plasma Lp(a) levels or do not result in clinical benefit. However, lipoprotein apheresis is very efficient in decreasing Lp(a) concentrations. A single apheresis session can acutely decrease Lp(a) by approximately 60-75%, and apheresis performed weekly or biweekly results in considerably decreased mean interval concentrations (approximately 25-40% reduction). While most apheresis systems (heparin-induced extracorporeal LDL precipitation, direct adsorption of lipoproteins, lipoprotein apheresis with dextran-sulfate, lipid filtration, immunoadsorption) decrease LDL and Lp(a), Lipopac is specific and only decreases Lp(a). Lp(a) apheresis is expensive and time consuming, but associated with very few side effects. Two randomized controlled trials give conflicting consults with respect to the effect on angiographic changes. Retrospective analyses indicate that regular apheresis translates into clinical benefit in patients with elevated Lp(a), but adequate randomized controlled trials are lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.